REPORT ID 2358

United States Fragile X Syndrome Market Report 2017

Publish Date
8-Dec-17
Pages
110
Format
Electronic (PDF)

In this report, the United States Fragile X Syndrome market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Fragile X Syndrome in these regions, from 2012 to 2022 (forecast).

United States Fragile X Syndrome market competition by top manufacturers/players, with Fragile X Syndrome sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Aelis Farma SAS
    Alcobra Ltd
    AMO Pharma Limited
    Confluence Pharmaceuticals LLC
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    Marinus Pharmaceuticals, Inc.
    MI.TO. Technology S.r.L.
    Neuren Pharmaceuticals Limited
    Ovid Therapeutics Inc.
    Sage Therapeutics, Inc.
    Zynerba Pharmaceuticals, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    ACT-01
    AMO-01
    ANAVEX-273
    AUT-00206
    Bryostatin-1
    Cannabidiol
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hopital
    Research Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Fragile X Syndrome Market Report 2017
1 Fragile X Syndrome Overview
    1.1 Product Overview and Scope of Fragile X Syndrome
    1.2 Classification of Fragile X Syndrome by Product Category
        1.2.1 United States Fragile X Syndrome Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Fragile X Syndrome Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 ACT-01
        1.2.4 AMO-01
        1.2.5 ANAVEX-273
        1.2.6 AUT-00206
        1.2.7 Bryostatin-1
        1.2.8 Cannabidiol
        1.2.9 Others
    1.3 United States Fragile X Syndrome Market by Application/End Users
        1.3.1 United States Fragile X Syndrome Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Clinic
        1.3.3 Hopital
        1.3.4 Research Center
    1.4 United States Fragile X Syndrome Market by Region
        1.4.1 United States Fragile X Syndrome Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Fragile X Syndrome Status and Prospect (2012-2022)
        1.4.3 Southwest Fragile X Syndrome Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Fragile X Syndrome Status and Prospect (2012-2022)
        1.4.5 New England Fragile X Syndrome Status and Prospect (2012-2022)
        1.4.6 The South Fragile X Syndrome Status and Prospect (2012-2022)
        1.4.7 The Midwest Fragile X Syndrome Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Fragile X Syndrome (2012-2022)
        1.5.1 United States Fragile X Syndrome Sales and Growth Rate (2012-2022)
        1.5.2 United States Fragile X Syndrome Revenue and Growth Rate (2012-2022)

2 United States Fragile X Syndrome Market Competition by Players/Suppliers
    2.1 United States Fragile X Syndrome Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Fragile X Syndrome Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Fragile X Syndrome Average Price by Players/Suppliers (2012-2017)
    2.4 United States Fragile X Syndrome Market Competitive Situation and Trends
        2.4.1 United States Fragile X Syndrome Market Concentration Rate
        2.4.2 United States Fragile X Syndrome Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Fragile X Syndrome Manufacturing Base Distribution, Sales Area, Product Type

3 United States Fragile X Syndrome Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Fragile X Syndrome Sales and Market Share by Region (2012-2017)
    3.2 United States Fragile X Syndrome Revenue and Market Share by Region (2012-2017)
    3.3 United States Fragile X Syndrome Price by Region (2012-2017)

4 United States Fragile X Syndrome Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Fragile X Syndrome Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Fragile X Syndrome Revenue and Market Share by Type (2012-2017)
    4.3 United States Fragile X Syndrome Price by Type (2012-2017)
    4.4 United States Fragile X Syndrome Sales Growth Rate by Type (2012-2017)

5 United States Fragile X Syndrome Sales (Volume) by Application (2012-2017)
    5.1 United States Fragile X Syndrome Sales and Market Share by Application (2012-2017)
    5.2 United States Fragile X Syndrome Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Fragile X Syndrome Players/Suppliers Profiles and Sales Data
    6.1 Aelis Farma SAS
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Fragile X Syndrome Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Aelis Farma SAS Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Alcobra Ltd
        6.2.2 Fragile X Syndrome Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Alcobra Ltd Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 AMO Pharma Limited
        6.3.2 Fragile X Syndrome Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 AMO Pharma Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Confluence Pharmaceuticals LLC
        6.4.2 Fragile X Syndrome Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Eli Lilly and Company
        6.5.2 Fragile X Syndrome Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Eli Lilly and Company Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 F. Hoffmann-La Roche Ltd.
        6.6.2 Fragile X Syndrome Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Marinus Pharmaceuticals, Inc.
        6.7.2 Fragile X Syndrome Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 MI.TO. Technology S.r.L.
        6.8.2 Fragile X Syndrome Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Neuren Pharmaceuticals Limited
        6.9.2 Fragile X Syndrome Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Ovid Therapeutics Inc.
        6.10.2 Fragile X Syndrome Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Sage Therapeutics, Inc.
    6.12 Zynerba Pharmaceuticals, Inc.

7 Fragile X Syndrome Manufacturing Cost Analysis
    7.1 Fragile X Syndrome Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Fragile X Syndrome

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Fragile X Syndrome Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Fragile X Syndrome Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Fragile X Syndrome Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Fragile X Syndrome Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Fragile X Syndrome Sales Volume Forecast by Type (2017-2022)
    11.3 United States Fragile X Syndrome Sales Volume Forecast by Application (2017-2022)
    11.4 United States Fragile X Syndrome Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer